Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalrestat Combined With HAIC, Donafenib and Tislelizumab in Unresectable HCC and Diabetes
NCT07557914Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epalrestat in hepatocellular carcinoma (HCC), diabetic neuropathy. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
epalrestat
03
Conditions
hepatocellular carcinoma (HCC)diabetic neuropathy
Beyond the preview
Go deeper on NCT07557914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557914.